Neoadjuvant therapy of pancreatic cancer: The emerging paradigm?

Oncologist

Volumn 17, Issue 2, 2012, Pages 192-200

  Lim, Kian Huat ^a   Chung, Eugene ^b   Khan, Adeel ^c   Cao, Dengfeng ^d   Linehan, David ^d   Ben Josef, Edgar ^b   Wang Gillam, Andrea ^d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c Aurora Health Care ^*  (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Borderline resectable; Borderline resectable chemotherapy; Chemoradiation; Neoadjuvant; Pancreatic cancer

Indexed keywords

AXITINIB; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; MITOMYCIN C; OXALIPLATIN; PACLITAXEL;

ADJUVANT CHEMORADIOTHERAPY; ADJUVANT THERAPY; ANASTOMOSIS LEAKAGE; ASPIRATION PNEUMONIA; BILE LEAKAGE; CANCER RECURRENCE; CHYLOUS ASCITES; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTINUOUS INFUSION; DISTANT METASTASIS; GASTROINTESTINAL HEMORRHAGE; HEART ARREST; HEMATOMA; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTRAOPERATIVE RADIOTHERAPY; LIVER METASTASIS; LYMPH NODE; MORBIDITY; MORTALITY; MULTIDETECTOR COMPUTED TOMOGRAPHY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PANCREAS CANCER; PANCREAS DISEASE; PANCREATICODUODENECTOMY; PERIOPERATIVE COMPLICATION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REVIEW; SEPSIS;

CHEMORADIOTHERAPY; HUMANS; NEOADJUVANT THERAPY; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; RADIOTHERAPY, INTENSITY-MODULATED; SURVIVAL RATE;

EID: 84857381194     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0268     Document Type: Review

References (53)

1. Howlader NNA, Krapcho M, Neyman N et al., eds. SEER Cancer Statistics Review, 1975-2008. Bethesda, MD: National Cancer Institute, 2011.
2. Griffin JF, Smalley SR, Jewell W, et al. Patterns of failure after curative resection of pancreatic carcinoma. Cancer 1990;66:56-61.
3. Sohn TA, Yeo CJ, Cameron JL et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000;4:567-579.
4. Oettle H, Post S, Neuhaus P et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA 2007;297:267-277.
5. Neuhaus P, Riess H, Post S et al., Deutsche Krebsgesellschaft (CAO/AIO). CONKO-001: Final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC). J Clin Oncol 2008; 26:abstr LBA4504.
6. Regine WF, Winter KA, Abrams RA et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 2008;299:1019-1026.
7. Neoptolemos JP, Stocken DD, Bassi C et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010;304:1073-1081.
8. Ohigashi H, Ishikawa O, Eguchi H et al. Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent threedimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer. Ann Surg 2009;250:88-95.
9. Palmer DH, Stocken DD, Hewitt H et al. A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: Gemcitabine alone versus gemcitabine combined with cisplatin. Ann Surg Oncol 2007;14:2088-2096.
10. Heinrich S, Schafer M, Weber A et al. Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial. Ann Surg 2008;248:1014-1022.
11. Ishikawa O, Ohigashi H, Imaoka S et al. Is the long-term survival rate improved by preoperative irradiation prior to Whipple's procedure for adenocarcinoma of the pancreatic head? Arch Surg 1994; 129:1075-1080.
12. Stessin AM, Meyer JE, Sherr DL. Neoadjuvant radiation is associated with improved survival in patients with resectable pancreatic cancer: an analysis of data from the surveillance, epidemiology, and end results (SEER) registry. Int J Radiat Oncol Biol Phys 2008;72:1128-1133.
13. Breslin TM, Hess KR, Harbison DB et al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol 2001;8:123-132.
14. Coia L, Hoffman J, Scher R et al. Preoperative chemoradiation for adenocarcinoma of the pancreas and duodenum. Int J Radiat Oncol Biol Phys 1994;30:161-167.
15. Pilepich MV, Miller HH. Preoperative irradiation in carcinoma of the pancreas. Cancer 1980; 46:1945-1949.
16. Vauthey JN, Dixon E. AHPBA/SSO/SSAT Consensus Conference on Resectable and Borderline Resectable Pancreatic Cancer: rationale and overview of the conference. Ann Surg Oncol 2009; 16:1725-1726.
17. Varadhachary GR, Tamm EP, Abbruzzese JL et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 2006;13:1035-1046.
18. NCCN. Pancreatic adenocarcinoma. National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology. Fort Washington, PA: National Comprehensive Cancer Network, 2008.
19. Patel M, Hoffe S, Malafa M, et al. Neoadjuvant GTX Chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer. J Surg Oncol 2011;104:155-161.
20. Katz MH, Pisters PW, Evans DB et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 2008;206:833-846; discussion 846-848.
21. Estrella JS, Rashid A, Fleming JB et al. Posttherapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation. Cancer 2011 [Epub ahead of print].
22. Gillen S, Schuster T, Meyer Zum Buschenfelde C et al. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and metaanalysis of response and resection percentages. PLoS Med 2010;7:e1000267.
23. Laurence JM, Tran PD, Morarji K et al. A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer. J Gastrointest Surg 2011;15:2059-2069.
24. Brunner TB, Grabenbauer GG, Meyer T et al. Primary resection versus neoadjuvant chemoradiation followed by resection for locally resectable or potentially resectable pancreatic carcinoma without distant metastasis. A multi-centre prospectively randomised phase II-study of the Interdisciplinary Working Group Gastrointestinal Tumours (AIO, ARO, and CAO). BMC Cancer 2007;7:41.
25. Heinrich S, Pestalozzi B, Lesurtel M, et al. Adjuvant gemcitabine versus NEOadjuvant gemcit-abine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: A randomized multicenter phase III study (NEOPAC study). BMC Cancer 2011;11:346.
26. Varadhachary GR, Wolff RA, Crane CH et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008;26:3487-3495.
27. Evans DB, Varadhachary GR, Crane CH et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008;26:3496-3502.
28. Conroy T, Desseigne F, Ychou M et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817-1825.
29. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25:1960-1966.
30. Van Cutsem E, Vervenne WL, Bennouna J et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009;27: 2231-2237.
31. Kindler HL, Ioka T, Richel DJ et al. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: A double-blind randomised phase 3 study. Lancet Oncol 2011;12:256-262.
32. Kindler HL, Friberg G, Singh DA et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2005;23:8033-8040.
33. Philip PA, Benedetti J, Corless CL et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 2010;28:3605-3610.
34. Ko AH, Youssoufian H, Gurtler J et al. A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma. Invest New Drugs 2011 [Epub ahead of print].
35. Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 2010;7:163-172.
36. Olive KP, Jacobetz MA, Davidson CJ et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009;324:1457-1461.
37. Beatty GL, Chiorean EG, Fishman MP et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011;331:1612-1616.
38. Hartwig W, Hackert T, Hinz U et al. Pancreatic cancer surgery in the new millennium: better prediction of outcome. Ann Surg 2011;254:311-319.
39. Evans DB, Rich TA, Byrd DR et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 1992;127:1335-1339.
40. Pisters PW, Abbruzzese JL, Janjan NA et al. Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. J Clin Oncol 1998;16:3843-3850.
41. Pisters PW, Wolff RA, Janjan NA et al. Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome. J Clin Oncol 2002; 20:2537-2544.
42. Hoffman JP, Weese JL, Solin LJ et al. A pilot study of preoperative chemoradiation for patients with localized adenocarcinoma of the pancreas. Am J Surg 1995;169:71-77; discussion 77-78.
43. Hoffman JP, Lipsitz S, Pisansky T et al. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: An Eastern Cooperative Oncology Group Study. J Clin Oncol 1998; 16:317-323.
44. Magnin V, Moutardier V, Giovannini MH et al. Neoadjuvant preoperative chemoradiation in patients with pancreatic cancer. Int J Radiat Oncol Biol Phys 2003;55:1300-1304.
45. Ohigashi H, Ishikawa O, Eguchi H et al. Feasibility and efficacy of combination therapy with preoperative and postoperative chemoradiation, extended pancreatectomy, and postoperative liver perfusion chemotherapy for locally advanced cancers of the pancreatic head. Ann Surg Oncol 2005; 12:629-636.
46. Mornex F, Girard N, Scoazec JY et al. Feasibility of preoperative combined radiation therapy and chemotherapy with 5-fluorouracil and cisplatin in potentially resectable pancreatic adenocarcinoma: The French SFRO-FFCD 97-04 Phase II trial. Int J Radiat Oncol Biol Phys 2006;65:1471-1478.
47. Talamonti MS, Small W Jr., Mulcahy MF et al. A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol 2006;13: 150-158.
48. Mehta VK, Poen JC, Ford JM et al. Protracted venous infusion 5-fluorouracil with concomitant radiotherapy compared with bolus 5-fluorouracil for unresectable pancreatic cancer. Am J Clin Oncol 2001;24:155-159.
49. Massucco P, Capussotti L, Magnino A et al. Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival. Ann Surg Oncol 2006;13:1201-1208.
50. Small W Jr., Berlin J, Freedman GM et al. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: A multicenter phase II trial. J Clin Oncol 2008;26:942-947.
51. Stokes JB, Nolan NJ, Stelow EB et al. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer. Ann Surg Oncol 2011;18:619-627.
52. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240:205-213.
53. DeOliveira ML, Winter JM, Schafer M et al. Assessment of complications after pancreatic surgery: a novel grading system applied to 633 patients undergoing pancreaticoduodenectomy. Ann. Surg 2006;244:931-937; discussion 937-939.